Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trio Plans Anti-COVID-19 Vaccine Derived From Simian Adenoviruses

Comprises Italy’s ReiThera, Germany’s Leukocare, Belgium’s Univercel

Executive Summary

Three European biotechs have joined forces to develop and manufacture a simian adenoviral vector-based vaccine candidate targeting the spike protein of SARS-CoV-2.

You may also be interested in...



Coronavirus Update: Double-Mutant Strain Discovered, India Puts Temporary Hold On AZ Vaccine Exports

Concern in India as a double-mutant strain with E484Q and L452R escape mutations has been found in the state of Maharashtra.

Coronavirus Notebook: UK Reveals Plans For Pre-Approval Use Of COVID-19 Vaccine

The UK government is proposing to take the "very unusual step" of making COVID-19 vaccines available before they are licensed. The international COVAX initiative is now supporting nine vaccines, and the EU and AstraZeneca have firmed up a vaccine purchase agreement.  

GSK bolsters vaccine business with Merck cast-off

GlaxoSmithKline has acquired Swiss vaccine developer Okairos for €250 million in cash. The privately held firm was spun out of Merck & Co in 2007.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142112

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel